Very little has changed in the management of advanced renal cell carcinoma since the approval of interleukin-2 (IL-2, aldesleukin [Proleukin]) in 1992 by the FDA for the systemic treatment of this disease. Dr. Bukowski succinctly reviews the
Bruce G. Redman, DO
Advertisement
Articles by Bruce G. Redman, DO
Advertisement
Latest Updated Articles
- Immunotherapy in Renal Cell Carcinoma
Published: June 1st 1999 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
CRT Does Not Improve RFS/OS, Confers High-Grade Toxicity in Cervical Cancer
2
Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era
3
ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC
4
Zipalertinib Yields Early Activity in EGFR+ NSCLC CNS Metastasis Population
5
